Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
=== Role in cancer progression and therapy resistance === ITGA1 contributes to tumor progression by regulating survival, migration, invasion, and resistance to anticancer therapies. In Pancreatic Ductal Adenocarcinoma (PDAC), ITGA1-mediated collagen EMT signaling promotes the survival of mesenchymal tumor cell populations, metastatic dissemination, and resistance to gemcitabine treatment. Inhibition of ITGA1 increases sensitivity to chemotherapy, making treatment more effective and supporting its capacity as a potential therapeutic target. In glioma, ITGA1 contributes to temozolomide (TMZ) resistance by activating the PI3K/AKT/Bcl-2 signaling pathway. Increased ITGA1 activity promotes anti-apoptotic signaling which prevents tumor cells from apoptosizing therefore leading to survival of tumor cells. Suppressing ITGA1 increases apoptosis and improves TMZ sensitivity. ITGA1 expression in glioma is regulated by the hsa-miR01298-5p pathway, which directly binds the ITGA1 3' untranslated region to suppress ITGA1 expression. Increased ITGA1 reverses those effects, making resistance to chemotherapy more likely.
Von Willebrand factor is normally synthesized in the endoplasmic reticulum of endothelial cells lining blood vessels (and also in megakaryocytes), and it is then packaged into multimers (many strands of vWF connected by disulfide bonds) by the Golgi and stored in Weibel-Palade bodies as a helical spiral of multiple multimers. When vWF is secreted by endothelial cells, the multimers are cleaved by the enzyme ADAMTS13 and vWF circulates in the plasma in a coiled and inactive form. When there is damage to a blood vessel (due to trauma or other factors) collagen under the blood vessel lining is exposed. When vWF comes into contact with exposed collagen it uncoils and binds to the collagen. Circulating platelets bind to vWF using their GpIb-alpha surface protein which binds to a specific area on the uncoiled vWF strand (The A1 domain binding site). Upon binding, the platelets become activated and irregularly shaped which attracts more platelets to the area of vascular damage to form a platelet plug in the blood vessel wall and stop the bleeding. In VWD, vWF is either deficient (type 1 disease), dysfunctional (type 2 disease), or is completely absent (the severe type 3 disease) leading to dysfunction in the above mechanism to stop bleeding. Circulating vWF also binds to coagulation factor VIII preventing it from being degraded. Factor VIII is involved in the coagulation cascade to also prevent excessive bleeding. Von Willebrand factor is mainly active in conditions of high blood flow and shear stress.
Indium has greater solubility in liquid mercury than any other metal (more than 50 mass percent of indium at 0 °C). Indium displays a ductile viscoplastic response, found to be size-independent in tension and compression. However it does have a size effect in bending and indentation, associated to a length-scale of order 50–100 μm, significantly large when compared with other metals.
Sources: en.wikipedia.org
Negotiations between France and the Viet Minh began in Geneva in May 1954 at the Geneva Conference, during which time the French Union and the Viet Minh were fighting a battle at Dien Bien Phu. In France, Pierre Mendès France was elected as Prime Minister on 17 June 1954 on a promise to achieve a ceasefire in four months.
Vapor diffusion is the most commonly employed method of protein crystallization. In this method, droplets containing purified protein, buffer, and precipitant are allowed to equilibrate with a larger reservoir containing similar buffers and precipitants in higher concentrations. Initially, the droplet of protein solution contains comparatively low precipitant and protein concentrations, but as the drop and reservoir equilibrate, the precipitant and protein concentrations increase in the drop. If the appropriate crystallization solutions are used for a given protein, crystal growth occurs in the drop. This method is used because it allows for gentle and gradual changes in concentration of protein and precipitant concentration, which aid in the growth of large and well-ordered crystals. Vapor diffusion can be performed in either hanging-drop or sitting-drop format. Hanging-drop apparatus involve a drop of protein solution placed on an inverted cover slip, which is then suspended above the reservoir. Sitting-drop crystallization apparatus place the drop on a pedestal that is separated from the reservoir. Both of these methods require sealing of the environment so that equilibration between the drop and reservoir can occur.
== Common ingredients == Antiscalants could be broadly classified into 3 main categories: phosphorus based AS, synthetic polymeric AS and natural green AS. Common active ingredients include phosphonates, polyphosphates, polymers, aminophosphonates and organic acids. Antiscalants typically contain a combination of active ingredients that interfere with the crystallization process of scale-forming salts. Phosphorus-based antiscalants have the largest application use globally, and they can be further classified into phosphorus-based and phosphonate-based AS. Green antiscalants usually contain natural polymers such as starch and are recently being more widely investigated due to discharge requirements. Polymer-based AS are synthetic polymers that have functional groups like carboxylic acid groups, acrylic acid, sulfonic acid, and phosphonic acid groups. Common global suppliers of antiscalants include Kurita Water Industries, Avista, Nalco, and Veolia.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\Lambda -\mu S-{\frac {\beta IS}{N}}\\[8pt]{\frac {dI}{dt}}&={\frac {\beta IS}{N}}-\gamma I-\mu I\\[8pt]{\frac {dR}{dt}}&=\gamma I-\mu R\end{aligned}}}
=== August === 1 August: The second Donald Trump administration raises tariffs on New Zealand exports to the United States to 15 percent. Visual effects company Wētā FX proposes laying off 100 jobs in its support departments based in Wellington. 4 August: The New Zealand Government announces plans to scrap the National Certificate of Educational Achievement (NCEA) secondary school qualification. A name suppression order lapses for former Deputy Commissioner of Police Jevon McSkimming, who was charged in June 2025 with eight counts of possessing objectionable material including child sexual exploitation and bestiality over a four-year period. 5–6 August — An RNZAF C-130J Hercules evacuated three personnel of the United States National Science Foundation from McMurdo Station. 6 August: The Christchurch-based wool factory Wild Earth Yarns acquires the woollen dye house and spinning mill of the liquidated Napier-based company Design Spun. Hato Hone St John proposes scrapping various community voluntary programmes including hospital volunteers, community carers and pet therapy services as part of a review of its services; affecting about 1,100 people. 8 August – The Japanese Navy makes a stop-over in Wellington for the first time since 1936. 9–10 August – Prime Minister Luxon hosts Australian Prime Minister Anthony Albanese in Queenstown for annual bilateral head of government talks. 10 August — Gloriavale Christian Community's Overseeing Shepherd Howard Temple resigns after pleading guilty to 12 charges of sexual offending against women and girls last month.
In his (August 1962) Report to the National Research Council of the National Academy of Sciences (AP.2), Archie Palmer reported that, of the 945 US "higher education institutions" he had surveyed, 349 had either "formulated and adopted a formalized research and patent policy", or were observing "a generally accepted practice with respect to the handling of research and patent matters", whilst the remaining 596 (which, he observed, conducted "little or no scientific or technological research") had "no formalized research or patent policies". In 1965, 96 US patents were granted to 28 "US universities or related institutions"; in 1992, 1500 US patents were granted to more than 150 "US universities or related institutions" (RH.2, p. 119). In 2025, the (formerly reluctant) University of California had been granted 571 patents, making the university's total "over 6,800 active patents" (JB.1). According to the economists Stanley Engerman and Gavin Wright (SE.1), (a) until 1933 there were more US patents issued to individuals than those issued to corporations, (b) by 1950 the ratio was 50:50, (c) by 1998, whilst the number of US patents issued to individual inventors remained more or less the same, (i.e., 10,000–15,000 per annum), they only represented approx. 10% of the number of patents issued.
Highland Council announces that Inverness's Hogmanay celebration will not take place in 2024–25 due to capacity and rising costs. 23 August – Edinburgh City Council votes to introduce a temporary fireworks ban around Bonfire Night in the city's Niddrie, Balerno, Seafield and Calton Hill districts, becoming the first Scottish council to implement such a ban. 25 August – BBC Scotland News reports that Scotland's local authorities are to divert money used to restore nature projects to pay for wage increases. 26 August – ASLEF suspends planned strike action for ScotRail drivers following a new pay offer, and will ballot its members on the offer. The Scottish Government confirms it will suspend the Connecting Scotland programme which provides iPads and laptops to people who are "digitally excluded" in order to pay for council pay rises. 28 August – Justice Secretary Angela Constance confirms that around 470 prisoners have been released under emergency provisions to release prisoners early from their sentences. 30 August – Cheyenne Naeb, an American philosophy student at the University of Dundee, who pushed a female member of railway staff in front of a stationary train at Glasgow Queen Street railway station in February 2023 after missing his train, is sentenced to 20 months in prison at Glasgow Sheriff Court. During a closed-door session at the SNP Party Conference, leader John Swinney tells delegates the party's losses at the election occurred because it spent too much time focusing on the "process of independence".
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.